Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endovascular mesenchymal cell therapy for knee osteoarthritis
IRCT20140818018842N43Phase 3Completed
- Sponsor
- Motamed Cancer Institute
- Start
- Sep 2024
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mesenchymal stromal cells in knee osteoarthritis (OA), sponsored by Motamed Cancer Institute. Primary endpoints: Change in WOMAC score, Change in VAS pain score and 2 more. Started Sep 2024; status: completed.
02
Drugs
mesenchymal stromal cells
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on IRCT20140818018842N43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20140818018842N43.